Delivery Order SPE2DB22D3501-SPE2DB25FXE70
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,191.84 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on August 21, 2025, with an ultimate completion date of August 22, 2025. This firm fixed price delivery order, which was competitively awarded without set-aside designation, is to be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Naloxone is a critical opioid antagonist medication used in emergency medical response and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $8,699.87. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The order is scheduled for completion by June 3, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Naloxone is a critical opioid...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Naloxone 4mg nasal spray (2-count units) with a ceiling value of $5,680.80. This competitively awarded, firm fixed-price delivery order was issued on April 24, 2025, with an ultimate completion date of the same day, indicating an expedited fulfillment requirement. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $5,241.60 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, will supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $10,635.64. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,498.38 delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-dose units) on July 14, 2025, with a completion date of July 15, 2025. This competitively awarded, firm fixed-price contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be fulfilled from the contractor's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Naloxone HCl 4 mg nasal spray (2-count units) with a ceiling value of $12,536.81. This firm fixed-price delivery order is scheduled for completion by September 30, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a delivery order valued at $1,572.48 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXE70Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,820.47 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order represents a non-set-aside award, indicating it was competitively awarded. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Naloxone is a critical emergency medication used to reverse opioid overdoses and is a standard pharmaceutical commodity within federal medical supply chains. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp has demonstrated substantial capacity to fulfill federal medical procurement requirements across multiple therapeutic domains, supporting military healthcare systems, the Defense Health Agency, and other government healthcare entities globally. The contract structure reflects DLA's reliance on established prime vendor relationships for efficient pharmaceutical distribution to support military operations and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 9/5/25 |